Xiaoyan He

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 7

Top Topics

High Fat Diet Induced

Molecular Docking

Acute Kidney Injury

Top Venues

Cell death discovery

Drug design, development and therapy

FASEB journal : official publication of the Federation of American Societies for Experimental Biology

This page only lists publications with an associated author ORCID identifier.

Publications

Liang Yu, Kai Yang, Xiaoyan He, Min Li, Lin Gao, Yunhong Zha
Repositioning linifanib as a potent anti-necroptosis agent for sepsis. Cell death discovery 9 (1) (2023)
Xiaoyan He, Min Li, Zhi Ye, Xiaoling You, Jia Wang, Xin Xiao, Guofeng Zhu, Jun Wei, Yunhong Zha
Identification of Piperlongumine as Potent Inhibitor of Necroptosis. Drug design, development and therapy 17 (2023)
Liang Yu, Kai Yang, Xiaoyan He, Min Li, Lin Gao, Yunhong Zha
Repositioning linifanib as a potent anti-necroptosis agent for sepsis. Cell death discovery 9 (1) (2023)
Liang Yu, Kai Yang, Xiaoyan He, Min Li, Lin Gao, Yunhong Zha
Repositioning linifanib as a potent anti-necroptosis agent for sepsis. Cell death discovery 9 (1) (2023)
Liang Yu, Kai Yang, Xiaoyan He, Min Li, Lin Gao, Yunhong Zha
Repositioning linifanib as a potent anti-necroptosis agent for sepsis. Cell death discovery 9 (1) (2023)
Xiaoyan He, Min Li, Zhi Ye, Xiaoling You, Jia Wang, Xin Xiao, Guofeng Zhu, Jun Wei, Yunhong Zha
Identification of Piperlongumine as Potent Inhibitor of Necroptosis. Drug design, development and therapy 17 (2023)
Min Li, Jun Wei, Guofeng Zhu, Shufang Fu, Xiaoyan He, Xinqian Hu, Yajie Yu, Yan Mou, Jia Wang, Xiaoling You, Xin Xiao, Tanrong Gu, Zhi Ye, Yunhong Zha
Quizartinib inhibits necroptosis by targeting receptor-interacting serine/threonine protein kinase 1. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 37 (10) (2023)